Dear Dr. Brophy:

Please refer to your supplemental new drug applications dated October 30, 2006, and received on October 31, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Zyprexa (olanzapine) Tablets, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg.


The September 19, 2008 submission constituted a complete response to our August 1, 2008 action letter.

These supplemental new drug applications provide for the use of Zyprexa (olanzapine) for the treatment of manic or mixed episodes of bipolar I disorder and schizophrenia in adolescents, a proposed modification to the approved Risk Evaluation and Mitigation Strategy (REMS), and a REMS assessment.

We have completed our review of these applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

On October 13, 2009, you submitted a proposed modification and an assessment of your Risk Evaluation and Mitigation Strategy (REMS), originally approved on March 19, 2009. The proposed modified REMS contains a revised Medication Guide which includes new indications for the use of Zyprexa in treating manic or mixed episodes of bipolar I disorder and schizophrenia in adolescents ages 13 to 17, and a timetable for submission of assessments revised to specify the dates the assessments are due and that the assessments will be received by FDA on or before the due dates.
Your proposed modified REMS, appended to this letter, is approved. The REMS consists of the Medication Guide and a timetable for submission of assessments.

There are no changes to the REMS assessment plan.

The requirements for assessments of an approved REMS under section 505-1(g)(3) include, in section 505-1(g)(3)(B) and (C), requirements for information on the status of any post-approval study or clinical trial required under section 505(o) or otherwise undertaken to investigate a safety issue. You can satisfy these requirements in your REMS assessments by referring to relevant information included in the most recent annual report required under section 506B and 21 CFR 601.70 and including any updates to the status information since the annual report was prepared. Failure to comply with the REMS assessment provisions in 505-1(g) could result in enforcement action.

We remind you that in addition to the assessments submitted according to the timetable included in the approved REMS, you must submit a REMS assessment and may propose a modification to the approved REMS when you submit a supplemental application for a new indication for use as described in section 505-1(g)(2)(A) of FDCA.

Prominently identify submissions containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission:

NDA 20592 REMS ASSESSMENT
NEW SUPPLEMENT FOR NDA 20592
PROPOSED REMS MODIFICATION
REMS ASSESSMENT

NEW SUPPLEMENT (NEW INDICATION FOR USE)
FOR NDA 20592
REMS ASSESSMENT
PROPOSED REMS MODIFICATION (if included)

If you do not submit electronically, please send 5 copies of REMS-related submissions.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm that is identical to the enclosed agreed-upon labeling text. Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, “SPL for approved NDA 20-592/S-040/S-041.”
We request that the revised labeling approved today be available on your website within 10 days of receipt of this letter.

**LETTERS TO HEALTH CARE PROFESSIONALS**

If you issue a letter communicating important safety related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch  
Food and Drug Administration  
5600 Fishers Lane, Room 12B05  
Rockville, MD 20857

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see [www.fda.gov/cder/ddmac](http://www.fda.gov/cder/ddmac).

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

**MEDWATCH-TO-MANUFACTURER PROGRAM**

The MedWatch-to-Manufacturer Program provides manufacturers with copies of serious adverse event reports that are received directly by the FDA. New molecular entities and important new biologics qualify for inclusion for three years after approval. Your firm is eligible to receive copies of reports for this product. To participate in the program, please see the enrollment instructions and program description details at [http://www.fda.gov/Safety/MedWatch/HowToReport/ucm166910.htm](http://www.fda.gov/Safety/MedWatch/HowToReport/ucm166910.htm).
If you have any questions, please call Kimberly Updegraff, M.S., Senior Regulatory Project Manager, at (301) 796-2201.

Sincerely,

{See appended electronic signature page}

Thomas Laughren, M.D.
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosures
  Content of Labeling
  REMS
<table>
<thead>
<tr>
<th>Application Type/Number</th>
<th>Submission Type/Number</th>
<th>Submitter Name</th>
<th>Product Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA-20592</td>
<td>SUPPL-40</td>
<td>ELI LILLY AND CO</td>
<td>ZYPREXA(OLANZAPINE) ORAL TABS 2.5MG/5MG/</td>
</tr>
<tr>
<td>NDA-20592</td>
<td>SUPPL-41</td>
<td>ELI LILLY AND CO</td>
<td>ZYPREXA(OLANZAPINE) ORAL TABS 2.5MG/5MG/</td>
</tr>
</tbody>
</table>

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

THOMAS P LAUGHREN
12/04/2009